Because SGLT2 inhibitors are recommended to patients with DKD or HF due to its cardiorenal protective effects [44], DKD patients in our study might be exposed more to SGLT2 inhibitors than no-DKD patients that can lead to underestimate the risk of DKD on HHF. The gene discussed is SLC5A2; the disease is hydrops fetalis.